Generic Name and Formulations:
Nintedanib 100mg, 150mg; caps.
Boehringer Ingelheim Pharmaceuticals
Indications for OFEV:
Treatment of idiopathic pulmonary fibrosis (IPF).
Swallow whole. Take with food. 150mg twice daily (approx. 12hrs apart); max 300mg/day. Mild hepatic impairment: 100mg twice daily (approx. 12hrs apart). Dose modifications due to adverse reactions: see full labeling.
Moderate or severe hepatic impairment: not recommended. Increased risk of liver enzyme elevation in low body weight, age, Asian, or female patients. Perform liver function tests prior to treatment, then as clinically indicated. Interrupt therapy if serious liver injury with symptoms and/or hyperbilirubinemia or jaundice occurs. GI disorders: treat at first signs with adequate hydration, antidiarrheals, or antiemetics; discontinue if severe diarrhea, nausea, or vomiting persists despite symptomatic treatment. Cardiovascular risk. Known coronary artery disease. Consider treatment interruption if signs/symptoms of acute myocardial ischemia develop. Risk of bleeding. Recent abdominal surgery. Discontinue if GI perforation develops. Smokers. Severe renal impairment (CrCl <30mL/min) or ESRD. Verify pregnancy status prior to initiation. Pregnancy: avoid. Females of reproductive potential should use effective contraception during treatment and at least 3 months after last dose. Nursing mothers: not recommended.
Avoid concomitant P-gp and CYP3A4 inducers (eg, rifampicin, carbamazepine, phenytoin, St. John’s wort). May be potentiated by P-gp and CYP3A4 inhibitors (eg, ketoconazole, erythromycin); monitor closely. Increased risk of bleeding with anticoagulants; monitor and adjust as necessary. Avoid smoking.
Diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight decreased, hypertension; arterial thromboembolic events, bleeding, GI perforation.
Psychiatry Advisor Articles
- Continuing Research, Emerging Treatments Hold Promise for Treating Anorexia Nervosa
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Is Antidepressant Use in Pregnancy Tied to Psychiatric Disorders in Offspring?
- Elevated Dopamine Synthesis Capacity Observed in Both Bipolar and Schizophrenia
- SSRI Use Associated With Increased Type 2 Diabetes Risk in Young Adults
- Specialty Physicians Experiencing Lack of Income Growth
- Improved Patient-Provider Communication Needed Following Urgent Care Visits
- Cardiovascular Risk Management May Slow Neurocognitive Decline in HIV